Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

Journal of Cellular Physiology

Volumn 226, Issue 11, 2011, Pages 2762-2781

  McCubrey, James A ^a   Steelman, Linda S ^a,b   Kempf, C Ruth ^b   Chappell, William H ^a   Abrams, Stephen L ^a   Stivala, Franca ^c   Malaponte, Graziella ^c   Nicoletti, Ferdinando ^c   Libra, Massimo ^c   Bäsecke, Jörg ^d   Maksimovic Ivanic, Danijela ^e   Mijatovic, Sanja ^e   Montalto, Giuseppe ^f   Cervello, Melchiorre ^g   Cocco, Lucio ^h   Martelli, Alberto M ^g,h  

^a EAST CAROLINA UNIVERSITY   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f UNIVERSITY OF PALERMO   (Italy)

^g CNR   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; AFATINIB; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BORTEZOMIB; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FK 506 BINDING PROTEIN; GEFITINIB; GROWTH FACTOR RECEPTOR; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; NILOTINIB; PD 0329501; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLX 4720; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAF PROTEIN; RAPAMYCIN; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER THERAPY; CELL GROWTH; DRUG RESISTANCE; DRUG SENSITIVITY; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; IONIZING RADIATION; MUTATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SECRETORY PATHWAY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; MICE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RAF KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79960237399     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22647     Document Type: Review

References (261)

1. Abbes B, Altaf AD, Alexander Z, Mark K, Wael E. 2008. t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Res 68: 395-403.
2. Abrams SL, Steelman LS, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. 2010a. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle 9: 1839-1846.
3. Abrams SL, Steelman LS, Shelton JG, Wong ET, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. 2010b. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9: 1781-1791.
4. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. 2006. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 38: 421-430.
5. Akiyama T, Dass CR, Choong PFM. 2009. Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther 8: 3173-3180.
6. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. 1997. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269.
7. Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T. 2005. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 280: 35195-35202.
8. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy DC, Miller WH Jr, Borden KL. 2009. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114: 257-260.
9. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. 2010. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal 3: ra67.
10. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. 2007. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. J Immunol 179: 5441-5453.
11. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. 2009a. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene 28: 3573-3585.
12. Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B. 2009b. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res 69: 8376-8385.
13. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC. 2008. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27: 2243-2248.
14. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. 2007. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937.
15. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
16. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. 2005. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120: 747-759.
17. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA Jr, Pelletier J. 2008. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest 118: 2651-2660.
18. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K, Cantrell DA. 1997. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 7: 679-689.
19. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, Greenberg ME. 2004. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011-2015.
20. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, Neumann CA. 2009. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 28: 1505-1517.
21. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX. 2006. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66: 8163-8171.
22. Carracedo A, Pandolfi PP. 2008a. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27: 5527-5541.
23. Carracedo A, Baselga J, Pandolfi PP. 2008b. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 7: 3805-3809.
24. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Koxma Sc, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. 2008c. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 18: 3065-3074.
25. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, Milanov ZV, Atteridge CE, Biggs WH 3rd, Edeen PT, Floyd M, Ford JM, Grotzfeld RM, Herrgard S, Insko DE, Mehta SA, Patel HK, Pao W, Sawyers CL, Varmus H, Zarrinkar PP, Lockhart DJ. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011-11026.
26. Casar B, Pinto A, Crespo P. 2009. ERK dimmers and scaffold proteins: unexpected partners for a forgotten task. Cell Cycle 8: 1007-1013.
27. Chalhoub N, Baker SJ. 2009. PTEN and the PI3-kinase pathway in cancer. Ann Rev Pathol Mech Dis 4: 127-150.
28. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. 2003. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293.
29. Chapuis N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Willems L, Agou F, Ifrah N, Dreyfus F, Bismuth G, Baud V, Lacombe C, Mayeux P, Bouscary D. 2010a. I{kappa}B kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia. Blood 116: 4240-4250.
30. Chapuis N, Tamburini J, Green AS, Willems L, Bardet V, Park S, Lacombe C, Mayeux P, Bouscary D. 2010b. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 24: 1686-1699.
31. Chapuis N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. 2010c. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 95: 415-423.
32. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira MS, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D. 2010d. Dual inhibition of PI3K and mTORC1/2 signalling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424-5435.
33. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, Braastad C, Sun Y, Mukhopadhyay A, Aggarwal BB, Darnowski J, Pantazis P, Wyche J, Fu Z, Kitagwa Y, Keller ET, Sedivy JM, Yeung KC. 2004. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279: 17515-17523.
34. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
35. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM. 2008. The novel Akt inhibitor perifosine induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 22: 1106-1116.
36. Cho KH, Shin SY, Kim HW, Wolkenbauer O, McFerran B, Kolch W. 2003. Mathematical modeling of the influence of RKIP on the ERK signaling pathway. Comput. Methods Syst Biol CSMB 2602: 127-141.
37. Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. 2007. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 28: 2321-2327.
38. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. 2005. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65: 10183-10187.
39. Coffer PJ, Woodgett JR. 1991. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 201: 475-481.
40. Corbit KC, Trakul N, Eves EM, Diaz B, Marshall M, Rosner MR. 2003. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem 278: 13061-13068.
41. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. 2007. Bim mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancer with oncogenic EGFR mutations. PLoS Med 4: 1669-1679.
42. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789.
43. Dai DL, Wang Y, Liu M, Martinka M, Li G. 2008. J. Bim expression is reduced in human cutaneous melanomas. Invest Dermatol 128: 403-407.
44. Datta K, Franke TF, Chan TO, Makris A, Yang SI, Kaplan DR, Morrison DK, Golemis EA, Tsichlis PN. 1995. AH/PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation. Mol Cell Bio 15: 2304-2310.
45. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. 1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-241.
46. Davis JM, Weinstein-Oppenheimer CR, Steelman LS, Navolanic PN, Hu W, Konopleva M, Blagosklonny MV, McCubrey JA. 2003. Raf-1 and Bcl-2 induce distinct and common pathways which contribute to breast cancer drug resistance. Clin Cancer Res 9: 1161-1170.
47. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nuñez G. 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278: 687-689.
48. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. 2003. Pathological and molecular aspects of prostate cancer. Lancet 361: 955-964.
49. Dey N, Crosswell HE, De PM Parsons R, Peng Q, Su JD, Durden DL. 2008. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68: 1862-1871.
50. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. 2008. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26: 5705-5712.
51. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. 2000. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204.
52. Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. 1994. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 54: 903-907.
53. Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC, Houghton PJ. 2002. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem. 277: 13907-13917.
54. Dourdin N, Schade B, Lesurf R, Hallett M, Munn RJ, Cardiff RD, Muller WJ. 2008. Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. Cancer Res 68: 2122-2131.
55. Downward J. 2003. Targeting Ras signaling pathways in cancer therapy. Nature Reviews Cancer 3: 11-22.
56. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD. 2010. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70: 2264-2273.
57. Du K, Montminy M. 1998. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273: 32377-32379.
58. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. 2009. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106: 20411-20416.
59. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
60. Fala F, Blalock WL, Tazzari P, Chappellini A, Chiarini F, Martinelli G, Tafuri A, McCubrey JA, Cocco L, Martelli AM. 2008. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor A43654 in T acute lymphoblastic leukemia. Mol Pharmacol 74: 884-895.
61. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, Cocito A, Amati B. 2003. Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
62. Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, Hibshoosh H, Parsons R. 2009. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 325: 1261-1265.
63. Fletcher JI, Huang DC. 2008. Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle 7: 39-44.
64. Franke TF, Kaplan DR, Cantley LC, Toker A. 1997. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3, 4-bisphosphate. Science 275: 665-668.
65. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L. 2007. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97: 1139-1145.
66. Fulco M, Sartorelli V. 2008. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle 7: 3669-3679.
67. Fulda S, Debatin KM. 2007. HIF-1-regulated glucose metabolism: a key to apoptosis resistance? Cell Cycle 6: 790-792.
68. Galle PR. 2008. Sorafenib in advanced hepatocellular carcinoma.-we have won a battle but not the war. J Hepatol 49: 821-828.
69. Garcia R, Franklin RA, McCubrey JA. 2006. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle 5: 2820-2826.
70. Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ. 2009. Apoptosis and autophagy: BIM as a mediator of tumor cell death in response to oncogene-targeted therapeutics. FEBS J 276: 6050-6062.
71. Graff JR, Konicek BW, Carter JH, Marcusson EG. 2008. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 68: 631-634.
72. Green AS, Chapuis N, Maciel TT, Willems L, Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, Viollet B, Ifrah N, Dreyfus F, Hermine O, Moura IC, Lacombe C, Mayeux P, Bouscary D, Tamburini J. 2010. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 116: 4262-4273.
73. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, Kumar R, Feng Z, Powell SN, Bhat A, Yaguchi T, Wadhwa R, Kaul SC, Parsons R, Khanna KK, Pandita TK. 2009. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8: 2198-2210.
74. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. 2008. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 21: 1156-1167.
75. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ, Kolch W. 2005. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 11: 7392-7397.
76. Hagan S, Garcia R, Dhillon A, Kolch W. 2006. Raf kinase inhibitor protein regulation of Raf and MAPK signaling. Methods Enzymol 407: 248-259.
77. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N. 2010. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70: 6804-6814.
78. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P. 1999. Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6: 559-568.
79. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK. 2005. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23: 2493-2501.
80. Hao J, Song X, Song B, Liu Y, Wei L, Wang X, Yu J. 2008. Effects of lentivirus-mediated HIF-1α knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cellsEffects of lentivirus-mediated HIF-1α knockdown. Cancer Gene Therapy 15: 449-455.
81. Harrison PM, Zheng D, Zhang Z, Carriero N, Gerstein M. 2005. Transcribed processed pseudogenes in the human genome: an intermediate form of expressed retrosequence lacking protein-coding ability. Nucleic Acids Res 33: 2374-2383.
82. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S. 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435.
83. Hayashi K, Shibata K, Morita T, Iwasaki K, Watanabe M, Sobue K. 2004. Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells. J Biol Chem 279: 40807-40818.
84. He L. 2010b. Posttranslational regulation of PTEN dosage by noncoding RNAs. Sci Signal 3: pe39.
85. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. 2005. A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
86. He L, Ingram A, Rybak AP, Tang D. 2010a. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest 120: 2094-2108.
87. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221.
88. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, Reddy SA, Sabapathy K., 2007. c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 14: 218-229.
89. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR. 2009. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase in basal-like breast cancer models. Clin Cancer Res 15: 4649-4664.
90. Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Goetz R, Rapp UR. 2004. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6.
91. Hresko RC, Mueckler M. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406-40416.
92. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. 2001. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276: 38830-38836.
93. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos, S, Wymann MP, Brosens JJ, Schulze A, Lam EW. 2008a. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 28: 5886-5898.
94. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ, Lam EW. 2008b. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 7: 670-678.
95. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM. 2008. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961.
96. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N. 2010. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 107: 14903-14908.
97. Junttila MR, Evan GI. p53-a jack of all trades but master of none. Nat Rev Cancer 9: 821-829.
98. Kane LP, Shapiro VS, Stokoe D, Weiss A. 1999. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 9: 601-604.
99. Keller ET, Fu Z, Brennan M. 2004. The role of Raf kinase inhibitor protein (RKIP) in health and disease. Biochem Pharmacol 68: 1049-1053.
100. Keniry M, Parsons R. 2008. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477-5485.
101. Kennedy SG, Kandel ES, Cross TK, Hay N. 1999. Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol Cell Biol 19: 5800-5810.
102. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. 2004. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA 101: 18105-18110.
103. Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, Borden KL. 2005. Further evidence that ribavirin interacts with eIF4E. RNA 11: 1762-1766.
104. Kim J, Freeman MR. 2003. JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 79: 321-328.
105. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New England J Med 352: 786-792.
106. Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S. 2005. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 92: 1711-1719.
107. Kops GJ, Burgering BM. 2000. Forkhead transcription factors are targets of signalling by the proto-oncogene PKB (C-AKT). J Anat 197: 571-574.
108. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR. 2010. Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res 16: 1865-1874.
109. Krymskaya VP, Goncharova EA. 2009. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 8: 403-413.
110. Kurmasheva RT, Huang S, Houghton PJ. 2006. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 95: 55-60.
111. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. 2006. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103: 14907-14912.
112. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, Rhee SG. 2004. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 101: 16419-16424.
113. Lassman AB, Rossi MR, Raizer JJ, Abrey LE, Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ, Cowell JK, DeAngelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland EC. 2005. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 21: 7841-7850.
114. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F. 2009a. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27: 5924-5930.
115. Laurent-Puig P, Lievre A, Blons H. 2009b. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 15: 1133-1139.
116. Lee JT Jr, McCubrey JA. 2002a Targeting the Raf kinase cascade in cancer therapy-novel molecular targets and therapeutic strategies. Expert Opin Ther Targets 6: 659-678.
117. Lee JT Jr, McCubrey JA, 2002b The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention. Leukemia 16: 486-507.
118. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. 2006. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 131: 1208-1217.
119. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, Martelli AM, Steelman LS, McCubrey JA., 2008a Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 7: 1745-1762.
120. Lee JT, Steelman LS, Chappell WH, McCubrey JA. 2008b Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle 7: 631-636.
121. Lefloch R, Pouyssegur J, Lenormand P. 2009. Total ERK1/2 activity regulates cell proliferation. Cell Cycle 8: 705-7011.
122. LeGouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004. 3: 1259-1262.
123. Leseux L, Hamdi SM, Al Saati, T, Capilla F, Recher C, Laurent G, Bezombes C. 2006. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 108: 4156-4162.
124. Leslie NR, Foti Michelangelo. (in press). Not in my genes: non-genomic loss of PTEN function in cancer. Trends Pharmacol Sci.
125. Ley R, Ewings KE, Hadfield K, Cook SJ. 2005. Regulatory phosphorylation of Bim: sorting out the ERK from JNK. Cell Death Differ 12: 1008-1014.
126. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. 2006. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 23: 575-587.
127. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
128. Lièvre A, Blons H, Laurent-Puig P. 2010. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 29: 3033-3043.
129. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 12: 3008-3019.
130. Lu J, Jeong HW, Kong N, Yang Y, Carroll J, Luo HR, Silberstein LE, Yupoma, Chai L. 2009. Stem cell factor SALL4 represses the transcriptions of PTEN and SALL1 through an epigenetic repressor complex. PLoS One 4: e5577.
131. Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM. 2010. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res 70: 3287-3298.
132. Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR. 2007. PTEN is destabilized by phosphorylation on Thr366. Biochem J 405: 439-444.
133. Maccario H, Perera NM, Gray A, Downes CP, Leslie NR. 2010. Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J Biol Chem 285: 12620-12628.
134. Mahimainathan L, Choudhury GG. 2004. Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279: 15258-15268.
135. Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW. 2007. Dissecting eIF4E action in tumorigenesis. Genes Dev 21: 3232-3237.
136. Marais R, Light Y, Paterson HF, Marshall CJ. 1995. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J14: 3136-3145.
137. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, Levine R, Michel K, Thomas RK, Rusch VW, Ladanyi M, Pao W. 2008. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 68: 5524-5528.
138. Martelli AM, Evangelisti C, Chirini F, Grimaldi C, Manzoli L, McCubrey JA. 2009. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18: 1333-1349.
139. Mavrakis KJ, Wendel HG. 2008. Translational control and cancer therapy. Cell Cycle 7: 2791-2794.
140. Mavrakis KJ, Zhu H, Silva RL, Mills JR, Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J, Wendel HG. 2008. Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev 22: 2178-2188.
141. Mavrakis KJ, Wolfe AL, Oricchio E, Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan AA, Leslie CS, Parker JS, Paddison PJ, Tam W, Ferrando A, Wendel HG. 2010. Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukemia. Nat Cell Biol 12: 372-379.
142. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M., 2006. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt pathways in malignant transformation and drug resistance. Adv Enzyme Regl 46: 249-279.
143. McCubrey J, LaHair M, Franklin RA. 2006. Reactive oxygen species-induced activation of the MAP kinase signaling pathway. Antioxid Redox Signal 8: 1745-1748.
144. McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Basecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM. 2008. Targeting survival cascades induced by activation of Raf/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 22: 708-722.
145. McCubrey JA, Abrams SL, Ligresti G, Misaghian N, Wong ET, Basecke J, Troppmair J, Libra N, Nicoletti F, Molton S, McMahon M, Evangelisti C, Martelli AM. 2008. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 22: 2080-2090.
146. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. 2009. Emerging Raf inhibitors. Exp Opin Emerg Drugs 14: 633-648.
147. McCubrey JA, Abrams SL, Stadelman K, Chappell WH, Lahair M, Ferland RA, Steelman LS. 2010a. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Advances Enzyme Regul 50: 285-307.
148. McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. 2010b. Emerging MEK inhibitors. Exp Opin Emerg Drugs 15: 203-223.
149. Mebratu Y, Tesfaigzi Y. 2009. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8: 1168-1175.
150. Mills JR, Hippo Y, Robert F, Chen SM, Malina A, Lin CJ, Trojahn U, Wendel HG, Charest A, Bronson RT, Kogan SC, Nadon R, Housman DE, Lowe SW, Pelletier J. 2008. mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci USA 105: 10853-10858.
151. Mobasheri A, Richardson S, Mobasheri R, Shakibaei M, Hoyland JA. 2005. Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol Histopathol 20: 1327-1338.
152. Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, Halperin JA, Wagner G. 2007. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128: 257-267.
153. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008. 4853-4861.
154. Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D'Andrea A, Sander C, Ventura A. 2009. Genetic dissection of the miR-17~92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev 23: 2806-2811.
155. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI. 2008. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 14: 447-457.
156. Myatt SS, Lam EWF. 2007. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859.
157. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2: 117-127.
158. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP. 2008. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 22: 2172-2177.
159. Navolanic PM, Steelman LS, McCubrey JA. 2003a. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 22: 237-252.
160. Navolanic PM, Lee JT, McCubrey JA. 2003b Docetaxol cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK pathway. Cancer Biol Ther 2: 29-30.
161. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F. 2004. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023.
162. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. 2004. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res 91: 169-200.
163. Odriozola L, Singh G, Hoang T, Chan AM. 2007. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J Biol Chem 282: 23306-23315.
164. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA. 2004. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11: 1192-1197.
165. Okahara F, Ikawa H, Kanaho Y, Maehama T. 2004. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem 279: 45300-45303.
166. Okahara F, Itoh K, Nakagawara A, Murakami M, Kanaho Y, Maehama T. 2006. Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3, 4, 5-trisphosphate signals and tumorigenic transformation. Mol Biol Cell 17: 4888-4895.
167. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. 2005. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA 102: 2703-2706.
168. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. 2006. PCAF modulates PTEN activity. J Biol Chem 281: 26562-26568.
169. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L. 2009. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 23: 2839-2849.
170. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM. 2010. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16: 793-798.
171. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. 2005. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17.
172. Park S, Rath O, Beach S, Xiang X, Kelly SM, Luo Z, Kolch W, Yeung KC. 2006. Regulation of RKIP binding to the N-region of the Raf-1 kinase. FEBS Lett 580: 6405-6412.
173. Park S, Chapuis N, Bardet V, Tamburini J, Gallay N, Willems L, Knight ZA, Shokat KM, Azar N, Viguié F, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. 2008. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia 22: 1698-1706.
174. Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D. 2010. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95: 819-828.
175. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. 2006. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 169: 2171-2180.
176. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP. 2010a. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3: ra29.
177. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP. 2010b. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 465: 1033-1038.
178. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
179. Pratilas CA, Solit DB. 2010. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 16: 3329-3334.
180. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB. 2008. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68: 9375-9383.
181. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N. 2009. (V600E) BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 106: 4519-4524.
182. Puc J, Parsons R. 2005b. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 4: 927-929.
183. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE, Piwnica-Worms H, Hibshoosh H, Parsons R. 2005a. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7: 193-204.
184. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE-B. 2000. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275: 10761-10766.
185. Qi XJ, Wildey GM, Howe PH. 2006. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 281: 813-823.
186. Qiao M, Sheng S, Pardee AB. 2008. Metastasis and AKT activation. Cell Cycle 7: 2991-2996.
187. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, Devreotes PN. 2009. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci USA 106: 480-485.
188. Rath O, Park S, Tang HH, Banfield MJ, Brady RL, Lee YC, Dignam JD, Sedivy JM, Kolch W, Yeung KC. 2008. The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cell Signal 20: 935-941.
189. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W. 2009. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119: 3000-3010.
190. Riely GJ, Marks J, Pao W. 2009. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6: 201-205.
191. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J. 2009. Altering chemosensitivity by modulating translation elongation. PLoS One 4: e5428.
192. Salmena L, Carracedo A, Pandolfi PP. 2008. Tenets of PTEN tumor suppression. Cell 133: 403-4414.
193. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
194. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. 2005. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
195. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. 2009a. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69: 1851-1857.
196. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. 2009b. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4: e7287.
197. Sato T, Nakashima A, Guo L, Tamanoi F. 2009. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. J Biol Chem 284: 12783-12791.
198. Scheijen B, Ngo HT, Kang H, Griffin JD. 2004. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 23: 3338-3349.
199. Schnitzer SE, Schmid T, Zhou J, Brune B. 2006. Hypoxia and HIF-1a protect A549 cells from drug induced apoptosis. Cell Death Differ 13: 1611-1613.
200. Schulte JH, Horn S, Otto T, Samans B, Heukamp LC, Eilers UC, Krause M, Astrahantseff K, Klein-Hitpass L, Buettner R, Schramm A, Christiansen H, Eilers M, Eggert A, Berwanger B. 2008. MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer 122: 699-704.
201. Sebolt-Leopold JS, English JM. 2006. Mechanisms of drug inhibition of signaling molecules. Nature 441: 457-462.
202. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N. 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297.
203. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N. 2010. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51.
204. Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, McMahon M, McCubrey JA. 2003. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia 17: 1765-1782.
205. Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA. 2005. The epidermal growth factor receptor as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opin Ther Targets 9: 1009-1030.
206. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. 2007. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170.
207. Shin SY, Rath O, Choo SM, Fee F, McFerran B, Kolch W, Cho KH. 2009. Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. J Cell Sci 122: 425-435.
208. Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY, Brenner MK, Nuchtern JG. 2002. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 62: 1123-1128.
209. Silva RL, Wendel HG. 2008. MNK, EIF4E and targeting translation for therapy. Cell Cycle 7: 553-555.
210. Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT., 2008. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. Clin Invest 118: 3762-3774.
211. Silva A, Jotta PY, Silveira AB, Ribeiro D, Brandalise SR, Yunes JA, Barata JT. 2010. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. Haematologica 95: 674-678.
212. Smalley KSM, Lioni M, Dalla Palma, M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, Elder DE, Flaherty KT, Herlyn M, Nathanson KL. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008. 2876-2883.
213. Sonenberg N, Hinnebusch AG. 2007. New modes of translational control in development, behavior and disease. Mol Cell 28: 721-729.
214. Staal SP. 1987. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84: 5034-5037.
215. Staal SP, Hartley JW. 1988. Thymic lymphoma induction by the AKT8 murine retrovirus. J Exp Med 167: 1259-1264.
216. Steelman LS, Bertrand FE, McCubrey JA. 2004. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 8: 537-550.
217. Steelman LS, Navolanic PN, Sokolosky M, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman K, Terrian DM, Leslie N, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA. 2008. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity of mTOR inhibitors. Oncogene 27: 4086-4095.
218. Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. 2010. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 9: 1629-1638.
219. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, Xu J. 2007. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67: 692-700.
220. Sun X, Vale M, Jiang X, Gupta R, Krissansen GW. 2010. Antisense HIF-1α prevents acquired tumor resistance to angiostatin gene therapy. Cancer Gene Ther 17: 532-540.
221. Sunters A, Ferandez de Mattos, S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW. 2003. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 278: 49795-49805.
222. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D, Chapuis, N, Tamburini J, Cornillet-Lefebvre P, Gillot L, Bardet V, Willems L, Park S, Green AS, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. 2008. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111: 379-382.
223. Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D. 2009a. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114: 1618-1627.
224. Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P, Bouscary D. 2009b. Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle 8: 3893-3899.
225. Tang Y, Eng C. 2006. p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Res 66: 6139-6148.
226. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, Martelli AM. 2007. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427-438.
227. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontandini A, Cocco L, McCubrey JA, Martelli AM. 2008. Synergistic proapoptotic activity of recombinant trail plus the akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res 68: 9394-9403.
228. Themsche C, Leblanc V, Parent S, Asselin E. 2009. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J Biol Chem 284: 20462-20466.
229. Toll A, Real FX. 2008. Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next? Cell Cycle 7: 2674-2681.
230. Ueda T, Watanabe Fukunga R, Fujuyama H, Nagata S, Fukunga R. 2004. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 6539-6549.
231. Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R, Mak TW. 2010. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA 107: 13984-13990.
232. Van Wang X, Jiang X. 2008. Post-translational regulation of PTEN. Oncogene 27: 5454-5463.
233. Vasudevan KM, Burikhanov R, Goswami A, Rangnekar VM. 2007. Suppression of PTEN expression is essential for antiapoptosis and cellular transformation by oncogenic Ras. Cancer Res 67: 10343-10350.
234. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, Kennedy NJ, Jiao J, Rose J, Xie W, Loda M, Golub T, Mellinghoff IK, Davis RJ, Wu H, Sawyers CL. 2007. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11: 555-569.
235. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. 1999. The antiapoptotic gene Mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 19: 6195-6206.
236. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X. 2007. NED4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139.
237. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. 1997. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. Embo J. 16: 1909-1920.
238. Waskiewicz AI, Hohnson JC, Penn B, Mahalingam M, Kimball SR, Cooper JA. 1999. Phosphoryaltion of the cap-binding protein eukaryotic translation initation factor 4E by protein kinase Mnk in vivo. Mol Cell Biol 19: 1871-1880.
239. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009. 69: 4286-4293.
240. Weinstein-Oppenheimer CR, Henríquez-Roldán CF, Davis J, Navolanic PM, Saleh OA, Steelman LS, Franklin RA, Robinson PJ, McMahon M, McCubrey JA. 2001. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 7: 2892-2907.
241. Weisberg E, Sattler M, Ray A, Griffin JD. 2010. Drug resistance in mutant FLT3-positive AML. Oncogene 29: 5120-5134.
242. Wendel HG, De Stanchina E, Friedman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
243. Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW. 2006. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66: 7639-7646.
244. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW. 2007. Dissecting eIF4E action in tumorigenesis. Genes Dev 21: 3232-3237.
245. West KA, Castillo S, Dennis PA. 2002. Activation of the PI3K/Akt pathway and chemotherapeutic drug resistance. Drug Resist Updates 5: 234-248.
246. Wilson BE, Mochon E, Boxer LM. 1996. Induction of bcl-2 expression by phosphorylated CREB proteins during B-Cell activation and rescue from apoptosis. Mol Cell Biol 16: 5546-5556.
247. Yang Y, Hou H, Haller EM, Nicosia SV, Bai W. 2005. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. Embo J 24: 1021-1032.
248. Yang H, Kong W, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. 2008. Micro RNA expression profiling in human ovarian cancer: miR-274 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433.
249. Yang J, Chai L, Gao C, Fowles TC, Alipio Z, Dang H, Xu D, Fink LM, Ward DC, Ma Y. 2008. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood 112: 805-813.
250. Yasuda T, Kurosaki T. 2008. Regulation of lymphocyte fate by Ras/ERK signals. Cell Cycle 7: 3634-3640.
251. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. 1999. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401: 173-177.
252. Yeung K, Janosch P, McFerran B, Rose DW, Mischak H, Sedivy JM, Kolch W. 2000. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein. Mol Cell Biol 20: 3079-3085.
253. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. 2001. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol 21: 7207-7217.
254. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. 2009. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15: 304-314.
255. Yu H, Li Y, Gao C, Fabien L, Jia Y, Lu J, Silberstein LE, Pinkus GS, Ye K, Chai L, Luo HR. 2010. Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. Leukemia 24: 1077-1080.
256. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. 2007. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11: 217-227.
257. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ. 2008. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105: 2070-2075.
258. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125: 1137-1149.
259. Zhao L, Vogt PK. 2008. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 105: 2652-2657.
260. Zhao L, Vogt PK. 2010. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (PI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 9: 596-600.
261. Zunder ER, Knight ZA, Houserman BT, Apsel B, Shokat KM. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α. Cancer Cell 2008. 14: 180-192.